ONCOLOGY AND IMMUNOPATHOLOGY ♋

PHARMACOLOGY

IMMUNOPATHOLOGY

NEOPLASIA

BASIC CONCEPTS

TUMOUR CLASSIFICATION AND TERMINOLOGY

TUMOUR CHARACTERISATION AND PROGRESSION

CLINICAL ASPECTS OF NEOPLASIA

MOLECULAR CARCINOGENESIS - SPORADIC AND INHERITED CANCER

ENVIRONMENTAL CAUSES OF CANCER - PHYSICAL, CHEMICAL AND MICROBIAL

CANCER SCREENING

SPECIFIC PATHOLOGICAL EXAMPLES

THE PATHOLOGY OF BONE AND SOFT TISSUE TUMOURS

BENIGN AND MALIGNANT PATHOLOGIES OF THE SKIN

BENIGN AND MALIGNANT PATHOLOGIES OF THE BREAST

THE PATHOLOGY OF BENIGN AND MALIGNANT(SOFT TISSUE) PAEDIATRIC TUMOURS

SERUM TUMOUR MARKERS MEASURED IN CLINICAL BIOCHEMISTRY

INTRODUCTION TO CHEMOTHERAPEUTICS

INTRODUCTION TO BIOTHERAPEUTICS

ANTICANCER TARGETS AND DRUGS

THE BASICS OF TUMOUR IMMUNOLOGY/IMMUNOTHERAPIES

CARE OF THE PATIENT WITH CANCER

CONNECTIVE TISSUE DISEASES

RHEUMATOID ARTHRITIS VS OTHER ARTHRITIDES

SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC SCLEROSIS, SJOGREN'S SYNDROME

INFLAMMATORY MYOPATHIES AND SYSTEMIC VASCULITIDES

IMMUNOSUPPRESSIVE AGENTS

ANTI-INFLAMMATORY AGENTS

TRANSPLANT REJECTION AND GRAFT VS HOST DISEASE

IMMUNODEFICIENCY

ALLERGY

AUTOIMMUNITY AND MALIGNANCY

Direct vs Indirect effects of the tumour on the host

TNM system for staging, T = primary tumour (extent of the primary lesion), N = extent of lymph node involvement, M = metastasis

Paraneoplastic syndromes - These are system complexes that cannot be explained by the local/metastatic spread of the tumour or the hormone production of the host tissue where the tumour arose. They can represent the earliest manifestation of an occult neoplasm and they may be clinically significant, lead to death, and can mimic metastatic disease e.g. acanthosis nigricans

  • Direct
  • local
  • bleeding
  • infections
  • rupture or necrosis of the tumour
  • location of the tumour → can cause impingement of adjacent structures or loss of function
  • sytemic
  • neoplastic fever
  • anaemia
  • functional activity e.g. effects on hormone production
  • hypercoaguability
  • paraneoplastic syndromes
  • cachexia
  • tumour spread
  • Indirect
  • cytotoxic chemotherapy
  • chemotherapy-induced apoptosis → non-selective targeting of rapidly growing cells e.g. in bone marrow, or the gastric lining
  • radiotherapy (effects depend on site and dose of radiation)
  • skin reactions
  • pneumonitis
  • cardiac toxicity
  • diarrhoea
  • infertility
  • secondary malignancies
  • targeted therapy (these often have less severe side effects than standard chemotherapy)
  • skin problems (anti-EGFR therapies)
  • bleeding (anti-VEGF therapies)
  • impaired wound healing
  • hepatitis
  • gastrointestinal perforation

Proto-oncogenes are genes that ar enormally expressed during regulated growth e.g. during embryogeneis or would healing. They are distributed throughout the human genome and have been evolutionarily conserved and hence are indispensable to normal cellular function

Molecular pathology tests used in cacner diagnosis

colorectal cancer

breast cancer

melanoma

non-small cell lung cancer

lymphomas and leukemias

BCL2 t(14;18)

JAK2

BRAF

MMR protein IHC = MLH1, MSH2, MSH6, PMS2

KRAS and NRAS

BRAF

HER2

ER and PR IHC

oncotype Dx

KRAS

EGFR

HER2

BRAF

For proto-oncogenes to become oncogenes that are capable of transformation, they must undergo:

The hereditary cancers include:

gene amplifaction e.g. HER2 and breast cancer

point mutation e.g. kRAS2 in colon cancer

translocation e.g. t(8;14) in Burkitt's lymphoma and Chronic Myeloid Leukaemia

hypomethylation

Retinoblastoma 13q

Breat and Ovarian cancer, BRCA1 on 17q and BRCA2 on 13q

Hereditary non-polyposis colorectal cancer/Lynch syndrome

Familial adenomatous poyposis 5q

Lifraumeni syndrome 17p

Chemical Carcinogenesis

Radiation Carcinogenesis

Microbial Carcinogenesis

Ionising radiation can cause chromosome breaks, double strand breaks, translocations, and less frequently, point mutations

UV rays can cause the formation of pyrimidine dimers and these result in skin cancer

Squamous cell carcinoma, basal cell carcinoma

Melanoma

Xeroderma Pigmentosa

Direct-acting carcinogens (alkylating agents)

Procarcinogens that require metabolic activation

Natural plant and microbial products

Viruses

Bacterial

Worms

Helicobacter pylori

HPV

EBV

Hepatitis B and C

HTLV-1

HIV

Human herpes virus 8

B cell Lymphomas

A subset of Hodgkin's Lymphomas

Indirect pathogenic involvement in Burkitt's lymphoma

cervical cancer

most commonly targeted genes are RAS and p53

COMMON BONE TUMOURS

SOFT TISSUE SARCOMAS

LIPOSARCOMA

ANGIOSARCOMA

LEIOMYOSARCOMA

RHABDOMYOSARCOMA

FIBROBLASTIC

UNCERTAIN LINEAGE

BENIGN BONE-FORMING TUMOURS

MALIGNANT BONE-FORMING TUMOURS

BENIGN CARTILAGE TUMOURS

MALIGNANT CARTILAGE TUMOURS

ROUND CELL TUMOURS

GIANT CELL RICH TUMOURS

FIBRO-OSSEOUS TUMOURS

VASCULAR BONE TUMOURS

Osteosarcoma

Osteoid osteoma

osteoblastoma

osteochondroma

enchondroma

chrondroblastoma

chondromyxoid fibroma

chondrosarcoma

fibrous dysplasia

osteofibrous dysplasia

Ewing's sarcoma

giant cell tumour

aneurysmal bone cyst

chondroblastoma

giant cell rich osteosarcoma

intraosseous haemangioma

epitheliod haemangioendothelioma

high-grade angiosarcoma of the bone

children and young adults

cortical based, long bones, nocturnal pain

medullary vertebral column

children and yound adults

bimodal age distribution, long bones

risk factors: paget's disease, prior irradiation, bone infarction

found on the surface of bone

metaphyseal region of the distal femur, upper humerus, tibia and fibula

medullary bone

mainly in the hands and feet

endochromatosis = the presence of multiple enchondromas e.g. with Ollier's disease or Maffucci syndrome

occurs in the epiphyses of long bones of skeletally immature patients

alteration of the K36M region of the H3F3A gene

seen in the pelvis, proximal femur, proximal humerus, distal femur and the ribs in people over 50

often associated with mutations of the IDH1 and/or the IDH2 genes

round cell diaphyseal intramedullary tumours

long bones > pelvis > ribs

associated with a recurrent chromosomal translocation t(11;22), fusion of the EWS gene on chr 22 to the FLI-1 gene on chr 11, and this results in the formation of a potent transcription factor

epiphyseal and intramedullary giant cell rich tumours

occur between the ages of 20 and 45

locally aggressive neoplasms with some metastasising to the lungs

skeletally immature patients

primary ABC associated with an alteration in the USP6 gene

can affect one or multiple bones

commonly found in the jaw, ribs, skull and long bones

most cases are associated with an alteration involving the GNAS gene

occur in the tibia of young patients

rarely progresses to an adamantinoma

benign tumour commonly effecting the spine

malignant vascular tumour

seen most commonly in adults

features epitheliod cells with vacuoles containg red blood cells/blister cells

associated with alteration that results in the fusion of the CAMTA1 and the WWTR1 genes

malignant vessel-forming tumour of the bone

occurs in adults, is aggressive and often multi-focal

graded using the French Federation of Cancer Centers Sarcoma Group, dependin on mitotic count, necrosis and tumour differentiation

myxofibrosarcoma

elderly patients, superficial aspects of limb girdles nd extremeties

synovial sarcomas

associated with a recurrent translocation involving the ss18 gene t(X;18)

desmoid fibromastosis

mainly sporadic but some associated with beta-catenin mutation (CTNNB1), or less commonly an APC gene mutation (Gardner syndrome)

Basic Principles

Two major components of the early detection of cancer

education to promote early diagnosis

screening

the condition should be an important health problem

there should be an available treatment for the disease

facilities for diagnosis and treatment should be available

there should be a latent stage of the disease

there should be a suitable test or examination

the test chould be acceptable to the population

the natural history of the disease should be adequately understood

there should be an agreed policy on whom to treat

the cost of case finding should be acceptable

case finding should be a continuous process

diagnostic test value assessment

sensitivity = true positives

specificity = true negatives

positive predictive value = the proportion of true positivies among all those testing positive

negative predicting value = proportion of true negatives among all those testing negative

lead time bias = apparent improvement in survival that is seen when screening advances the time of diagnosis without any change in the actual time of death

length-time bias = tendency of screening to detect a disproportionate number of cases of slowly progressing cancer compared with more aggressive cases, and aggressive cases may progress during the screening interval

Cancer screening programmes in Ireland

Cervical cancer screening - smear test

Breast cancer screening - mammogram

Colorectal cancer screening - free faecal immunochemical testing

EPIDERMAL TUMOURS

MELANOCYTIC TUMOURS

SYNDROMES ASSOCIATED WITH ADNEXAL NEOPLASMS

BROOKE SPIEGLER SYNDROME

MUIRR-TORRE SYNDROME

COWDEN SYNDROME

BURT HOGGE DUBE SYNDROME

SEBORRHEIC KERATOSIS

VERUCCA VULGARIS

ACTINIC KERATOSIS

BOWEN'S DISEASE/SQUAMOUS CELL CARCINOMA-IN-SITU

SQUAMOUS CELL CARCINOMA

BASAL CELL CARCINOMA

BENIGN NAEVI (MOLES)

DYSPLASTIC NAEVI

MELANOMA

prognosis depends on:

depth of invasion

presence of ulceration

clinical stage at diagnosis

measured using the Breslow thickness scale and the Clark level MELANOMA MEASUREMENT

available therapy:

BRAF inhibitor therapy if BRAF V600 gene mutation present

PDL1 inhibitor therapy if IHC determines eligibility

allows for the avoidance of attack from our own T lymphocytes

adnexal tumours arise from sebaceous glands, hair follicles and sweat ducts

malignant melanocytes invading into the dermis

risk factors:

UV light exposure

family history

multiple naevi

immunosuppression

very common

usually congenital but can occur after this, pay attention to those occuring in the middle/older age groups

can recur

naevi >5mm in diameter

irregular borders

varied pigmentation

changing naevi

multiple naevi

dysplastic naevus syndrome

increased risk of melanoma

autosomal dominant mutation

mutation affecting the CDKN2A gene

100 naevi, both regular and atypical

affects the epithelium of the hair follicle rather than squamous cells in the epidermis

locally recurrent

no metastasis

can be associated with Nevoid basal cell carcinoma (Gorlin) syndrome

adults

sharply demarcated and pigmented lesions that protude above the skin surface

can have a greasy appearance

benign proliferation of keratinocytes with horn cysts

associated with a HPV infection

firm outgrowth of keratinocytes with horn cysts

common on hands and feet

common

seen in sun exposed areas

no invasion of the dermis

most are adequately treated with currettage

UV light exposure is a risk factor but can occur in both sun exposed and non-sun exposed areas

risk factors

UV light exposure

burns

irradiation

immunosuppression

prognosis depends on

size

depth of invasion

lymphovascular invasion

germline mutation in the cylindromatosis gene on chromosome 16

autosomal dominant disorder

cylindromas

spiradenomas

trichoepitheliomas

autosomal sominant mutation in the MLH1 and MSH2 mismatch repair genes

a lynch syndrome variant

patients at risk for: colorectal and endometrial adenocarcinoma, and cutaneous sebaceous tumours

autosomal dominant mutation in the PTEN tumour suppressor gene

multiple hamartomas

increased life time risk of thyroid, breast, endometrial, colorectal cancer and melanoma

skin manifestations

facial fibrous papules

trichilemmomas

palmar/plantar keratoses

autosomal dominant mutation in the BDH or FLCN gene on chromosome 17 coding for the folliculin protein

skin lesions (occur mainly on the face and upper chest)

fibrofolliculomas

trichodiscoma

angiofibroma

patients are also at risk fro developing lung cysts with pneumothorax and renal cell carcinoma, in particular bilateral chromophobe renal cell carcinoma and oncocytoma

BENIGN BREAST DISEASE

MALIGNANT BREAST DISEASE

RISK FACTORS

fmaily history (BRCA1 gene)

reproductive profile - uninterrupted oestrogen stimulation e.g. with nuns, abstinence

exogenous hormones - the pill, HRT

lifestyle - alcohol, diet, smoking

environmental - radiation

sociodemographic

Molecular classification:

chemo useful for:

chemo not useful for:

predictive indices (response to treatment)

prognostic indices

tumout type

tumour grade

tumour size

lymph node status

hormone receptor status

human epidermal growth factor status

multigene panel studies

mutational studies

luminal = HER2 negative, ER/PR positive

HER2 rich = HER2 positive

triple negative = HER2 negative, ER/PR negative

lymph node positive

HER2 positive

triple negative

small tumours

grade 1 tumours

lymph node negative

ER positive

HER2 negative

types:

ductal no-special type

special type carcinoma

mixed type

cysts

duct ectasia

fibroadenoma

phyllodes tumour

radial scar

papilloma

remove by excision to exclude malignancy

benign lesion with a duct

surveillance of tumour or excision, depending on the grade of the tumour

peri-areolar abscess

affects ducts of the breast

causes

smoking

bacteria

hyperprolactinaemia

dilatation

accumulation of secretions

inflammation and fibrosis

fluid filled dilated breast gland (acinus)

treatment with subareolar exploration and removal of tissue

treatment with aspiration

complete excision to exclude malignancy

spiculate lesion with irregular outline

benign tubules in the sclerotic stroma

NEUROBLASTOMA

RHABDOMYOSARCOMA

WILMS TUMOUR

HEPATOBLASTOMA

EWINGS SARCOMA

LANGERHAN'S CELL HISTIOCYTOSIS

bone/soft tissue tumour

found in the chest wall and the long bones

confirmation with CD99 IHC staining

most commonly associated with translocation t(11;22)

affects multiple systems of the body

if BRAF mutation present, then it can be treated with vemurafenib (a BRAF inhibitor)

CD1a cell surface marker can be identified on IHC

primitive embryonic tumour of the liver

commonly seen in premature babies and very low birth weight infants

associated syndromes:

familial adenamatous polyposis

Beckwith Wiedmann syndrome

Li-Fraumeni syndrome (p53 mutation)

trisomy 18

mutation in the betacatennin pathway and APC gene inactivation

features

rasied AFP

mass

abdominal pain

vomiting

failure to thrive

soft tissue tumour that usually appears in the first decade of life

malignant

commonly found:

combined treatment

head and neck

extremities

GI tract

bladder

pelvis

orbit

vagina

renal tumour

cases peak between 1 and 5 years of age

presents with

clinical and genetic associations

pain

haematuria

hypertension

signs of rupture

huge mass

WAGR

DRASH

WT1 gene on 11p

genetic imprinting disorders e.g. Beckwith Wiedmann syndrome

hemihypertrophy

loss of heterozygosity on chromosome 1p and 16q

extra-cranial tumour of the autonomic nervous system

25% of cases are congenital, but otherwise they occur before the age of 5

found:

adrenal medulla

paravertebral

retroperitoneal

posterior mediastinum

50-60% present with metastases

other neuroblastic tumours include ganglioneuroblastoma and ganglioneuroma, which are more benign than neuroblastoma

treatment:

intensive chemotherapy in tandem with a bone marrow transplant

if ALK mutation present, crizotinib (an ALK kinase inhibitor) can be used

anti-GD2 immunotherapy

MKI = the mitotic karryhorhectic index and it measures how rapidly cells are dividing/dying and is measured as a percentage. The lower the percentage, the better the prognosis and the higher the percentage, the worse the prognosis

tumour presence indicators:

location specific issues

tumour secretions

cell/tissue destruction

a good biomarker has:

high specificity - screening

high sensitivity - diagnosis

correlation with tumour stage for monitoring

correlation with patient prognosis for outcome

specific tumour markers used

hCG

AFP

CEA

CA 125, 19-9, 15.3

PSA

gestational trophoblastic disease

non-malignant liver conditions e.g. cirrhosis, hepatitis, cholestasis

hepatocellular carcinoma/hepatoblastoma

germ cell tumours of the testes/ovaries

ovarian cancer, adenocarcinoma of the pancrease, and carcinoma of the breast (respectively)

colorectal cancer

CLASSIFICATION OF AUTOIMMUNE DISEASES

GENERAL CHARACTERISTICS OF AUTOIMMUNE DISEASE

CLINICAL COURSE OF AUTOIMMUNE DISEASES Untitled (1)

ORGAN SPECIFIC e.g. inflammatory bowel disease (IBD)

SYSTEMIC e.g. rheumatoid arthritis

middle aged females most commonly affected

genetic predisposition and environmental factors

multi-organ involvement and inflammatory signs

immunological abnormalities e.g. auto antibodies

well defined clinical picture and disease course

chronic and often fluctuates between periods of flares and remission

early diagnosis is crucial

have diagnostic criteria and severity based on disease activity and damage

IMMUNE-RELATED ARTHRITIDES

NON-IMMUNE RELATED ARTHRITIDES

RHEUMATOID ARTHRITIS

SERONEGATIVE SPONDYLOARTHROPATHIES

DEGENERATIVE DISORDERS

METABOLIC DERRANGEMENTS

INFECTIONS

SEPTIC ARTHRITIS

GOUT

OSTEOARTHRITIS

absence of rheumatoid factor

HLA-B27 association

commonly associated with the sacroiliac joints

pathological changes in the enthesis rather than the synovium

examples:

ankylosing spondylitis

reactive arthritis

psoriatic arthritis

enteropathic arthritis

a degenerative joint disease characterised by the progressive erosion of cartilage

signs and symptoms:

joint involvement:

oligoarticular (usually more than one)

asymmetrical

weight breaing joints

small joints of the hands

small joints of the feet

pain that worsens with use and eases with rest

short-lived morning stiffness

crepitus

decreased range of movement

wastage of surrounding muscle groups

joint effusion

tenderness

compression of spinal roots of the C-spine

aetiology

diagnosis

signs and symptoms

treatment (combination therapy)

pathogenesis

NSAIDs

DMARDs e.g. methotrexate

Glucocorticoids e.g. prednisolone

cytokine mediated inflammation

autoantibody-mediated inflammation - anti citrullinated protein antibodies or rheumatoid factor

general features:

inflammation of joints, tendons and bursae

early morning stiffness (>30 minutes) that is relieved with physical activity

reduced joint function

joint abnormalities occur in severe RA

malaise

weakness

fatigue

musculoskeletal pain

low grade fever

weightloss

swelling

warmth

pain

tenderness

ACR/EULAR criteria acr criteria

genetic predisposition

environmental factors

smoking

infections

dietary factors

gut microbiome

HLA-DR4

PTPN22

PADI4

SLE

SYSTEMIC SCLEROSIS

SJOGREN'S SYNDROME

GENETIC ASSOCIATIATIONS

CLINICAL MANIFESTATIONS

Sjogren's syndrome is the immune mediated destruction of exocrine glands

HLA-DR52

IRF-5 (interferon regulating factor)

STAT4

HLA-DR3, HLA-DQ2 and HLA-B8 seen in caucasians

lacrimal glands - keroconjunctivitis sicca, dry eyes

salivary glands - chronic sialoadenitis, xerostomia (dry mouth)

also an increased risk for the development of non-hodgkin's lymphoma

Systemic Sclerosis is a systemic autoimmune disorder that is characterised by chronic inflammation, widespread small vessel damage and progressive perivascular and interstitial fibrosis

T-cells, autoantibodies and pro-fibrotic cytokines activity stimulates fibroblasts

CLINICAL MANIFESTATIONS

skin manifestations - thickened skin, claw-like hands, microstomia,

raynaud's phenomenon

lung manifestations - pulmonary hypertension (main cause of death)

Limited cutaneous systemic sclerosis

Diffuse cutaneous systemic sclerosis

anti-centromere antibody

CREST syndrome

Calcinosis

Raynaud's phenomenon

Esophageal dysmotility

Sclerodactyly

telangiectasia

anti-topoisomerase I antibody

widespread skin involvement

organ failure within 5 years

Clinical Manifestations

Diagnostic criteria

Common feature: positive antinuclear antibodies

DIF ANA patterns

Lupus specific ANAs

anti-dsDNA

anti-Sm

homogenous

rim/peripheral

speckled

nucelolar

American College of Rheumatology criteria = A RASH POINTs MD

Systemic Lupus Internation Collaborating clinic criteria

clinic criteria e.g. arthritis, serositis

immunological crtieria

Skin manifestations

Kidney manifestations

Haematological manifestations

Cardiopulmonary manifestations

Ocular manifestations

Sjogren's syndrome

anaemia

leukocytopaenia

Libman-Sacks endocarditis

Shrinking lung syndrome

lupus nephritis

photosensitivity

malar/butterfly rash

lupus profundus

INFLAMMATORY MYOPATHIES

SYSTEMIC VASCULITIDES

DERMATOMYOSITIS

POLYMYOSITIS

bilateral proximal muscular weakness but no rash

poor prognosis if there is interstitial lung disease

CD8+ cytotoxic T cells causing direct injury

20% present with anti-Jo1 antibodies (common to all inflammatory myopathies)

CLINICAL MANIFESTATIONS

SKIN

MUSCLE

heliotrope rash

gottron's papules

shawl sign - erythermatous rash on shoulders, back and trunk

pruritic rash

mechanic's hand - rough surface with lots of cracks

telangectiasia

progressive and symmetric proximal muscle weakness

fine motor movements affected as the disease progresses

pharyngeal muscles and neck flexors are commonly involved, resulting in dysphagia and head drop

facial and ocular muscles are usually spared

normal sensation and tendon reflexes maintained

anti-M2 antibodies - anti-helicase is dermatomysositis specific

LARGE VESSEL VASCULITIS

MEDIUM VESSEL VASCULITIS

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) ASSOCIATED SMALL VESSEL VASCULITIS

IMMUNE COMPLEX SMALL VESSEL VASCULITIS

MICROSCOPIC POLYANGIITIS

CHURG-STRAUSS SYNDROME

WEGENER'S GRANULOMATOSIS

IgA VASCULITIS

HENNOCH SCHNLEIN PURPURA

GIANT CELL ARTERITIS

TAKAYASU'S ARTERITIS

KAWASAKI DISEASE

POLYARTERIITIS NODOSA

affects extra cranial branches of the carotid arteries mainly

can go blind

treatment is with steroids

features: multinucleated giant cells in the elastic lamina and the presence of mononuclear infiltrate, scarring with intimal thickening, residual elastic fragmentation and adventitial fibrosis

commonly affects the aorta and it's branches

affects infants and childre - boys under 4

self-limiting

mucocutaneous lymph node syndrome

CRASH clinical symptoms

treatment with IC immunoglobulins

Conjunctivitis

Rash

Fever

Adenopathy

Strawberry tongue

Hands and feet - rash and swelling

affects renal and visceral vessels but not pulmonary vessels

affects young adult males

segmental transmural necrotising inflammation